This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
It is no longer the current profile. Read the canonical profile and its correction notice.
What this version reported
FDA's compounding-risk page describes immunogenicity, impurity, and adverse-event concerns. A separate Justice Department release names CJC 1295 among unapproved new drugs distributed by the cited pharmacy.↗↗
Organizations named in cited records:
- U.S. Food and Drug Administration↗
Sources for this version
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
- 2Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026